Compare Bristol-Myers Squibb Co (BMY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nano Dimension Ltd - ADR — how do they compare? Bristol-Myers Squibb Co trades at $58.65 (market cap $116.30B), while Nano Dimension Ltd - ADR trades at $1.49 (market cap $314.71M). The key difference: Bristol-Myers Squibb Co is far larger — about 369.5× Nano Dimension Ltd - ADR's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| BMY | NNDM | |
|---|---|---|
Market Cap | $116.30B | $314.71M |
Sector | Health | Technology |
52-Week High | $62.37 | $2.14 |
52-Week Low | $42.60 | $1.21 |
Enterprise Value | $152.24B | -$94.63M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Nano Dimension (NNDM) trades at $1.48, down 1.33% with a bearish technical signal. The company reported Q1 2026 revenue of $102.44M but a net loss of -$293.30M, reflecting a -286.72% margin. Cash burn remains high at -$101.28M from operations. Recent news highlights board disputes with shareholder Murchinson and a proposed merger with Infinite Epigenetics, creating uncertainty.
The outlook is challenged by persistent losses and negative cash flow, though the P/B of 0.64 suggests undervaluation. Risks include execution on strategic plans and shareholder activism. Analyst sentiment is cautious given the lack of profitability and ongoing corporate governance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
